Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GRN | P28799 | 1/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.44 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6522512 | 0.91 | KMT2A (0.44) | LMNAHDAC4HDAC3HDAC1HDAC7 | |
| SCHEMBL6522516 | 0.91 | KMT2A (0.44) | LMNAHDAC4HDAC3HDAC1HDAC7 | |
| SCHEMBL8221672 | 0.84 | LMNA (0.48) | GPR132LMNAGRNSORT1 | |
| SCHEMBL5970365 | 0.81 | EPHX2 (0.54) | — | |
| SCHEMBL15864738 | 0.81 | GPR132 (0.57) | GPR132LMNAHDAC3HDAC1HDAC2 | |
| SCHEMBL1133842 | 0.79 | LMNA (0.51) | GPR132LMNAHDAC4HDAC3HDAC1 | |
| SCHEMBL2121460 | 0.79 | LMNA (0.51) | GPR132LMNAHDAC4HDAC3HDAC1 | |
| SCHEMBL210916 | 0.79 | LMNA (0.51) | GPR132LMNAHDAC4HDAC3HDAC1 | |
| SCHEMBL8583252 | 0.79 | LMNA (0.46) | GPR132LMNAHDAC1HDAC6 | |
| SCHEMBL15967436 | 0.79 | MEN1 (0.46) | LMNAHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028674-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2018-02-01 | — | — | US | disclosed |
| US-RE46608-E1 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-RE46605-E1 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-3210972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | Catabasis Pharmaceuticals, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20160346397-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9486534-B2 | Niacin conjugated fatty acid mixtures and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2473045-B1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9278136-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9238077-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20140113940-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| WO-2013177536-A2 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-8304552-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304551-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120264791-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120252850-A1 | NIACIN CONJUGATED FATTY ACID MIXTURES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120184585-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2473045-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | Catabasis Pharmaceuticals, Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011028689-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110053990-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053990-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | GPR132 3109/4885LMNA 1041/4885GRN 2951/4885 |
| US-20120184585-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | GPR132 3109/4885LMNA 1041/4885GRN 2951/4885 |
| US-20140113940-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | GPR132 3109/4885LMNA 1041/4885GRN 2951/4885 |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | GPR132 2927/4885LMNA 529/4885GRN 3172/4885 |
| US-20120264791-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | GPR132 3109/4885LMNA 1041/4885GRN 2951/4885 |
| US-20120252850-A1 | NIACIN CONJUGATED FATTY ACID MIXTURES AND THEIR USES | FABP1, NAMPT, ADH1B | GPR132 2549/4885LMNA 990/4885GRN 3335/4885 |
| US-20180028674-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | GPR132 3109/4885LMNA 1041/4885GRN 2951/4885 |
| US-20160346397-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | GPR132 3109/4885LMNA 1041/4885GRN 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.